The study included 48 untreated patients with monoclonal gammopathies (MG). Paraprotein was isolated from the serum of 10 patients with decreased platelet aggregation. Platelet aggregation was measured before and after the addition of the isolated paraprotein to platelet-rich plasma (PRP) from 10 healthy donors, in vitro. Expression of platelet von Willebrand factor (vWF) receptor glycoprotein (GP)Ib and platelet collagen receptor GPVI was determined by flow cytometry in the PRP of healthy donors before and after the addition of isolated paraprotein using the monoclonal antibodies, CD42b (for GPIb) and CD36 (for GPVI). Flowcytometry showed that expression of CD42b and CD36 positive cells was reduced after the addition of isolated paraprotein to PRP from healthy donors (p < 0.001). These investigations demonstrated that paraprotein causes platelet dysfunction in patients with MG due to specific binding to the platelet vWF receptor GPIb and platelet collagen receptor GPVI.

1.
Apitz K: The disturbance of protein metabolism in plasmocytoma. Klin Wschr 1940;19:1058-1061.
2.
Tricot G: Multiple myeloma and other plasma disorders; in Hoffman R et al (eds): Hematology, Basic Principles and Practice, ed 4. New York, Churchill Livingstone, 2005, pp 1501-1535.
3.
Kawai T: Plasma protein changes in M-proteinemic type; in Kawai T (ed): Clinical Aspects of Plasma Proteins. Berlin, Springer, 1973, pp 305-373.
4.
Garver FA, Chang L, Mendicino J, Isobe T, Osserman EF: Primary structure of deleted human lambda type immunoglobulin light chain containing carbohydrate: protein Sm λ. Proc Natl Acad Sci (USA) 1975;72:4559-4563.
5.
Decourt C, Cogne M, Rocca A: Structural peculiarities of truncated VκIII-immunoglobulin light chain deposition disease. Clin Exp Immunol 1996;06:357-361.
6.
Werner BG, Steinberg AG: Structural studies of human hybrid immunoglobulin. Immunogenetics 1974;3:254-271.
7.
Lefranc G, Helal AN, de Lange G: Gene conversion in human immunoglobulin G locus shown by unusual location of IgG allotypes. FEBS Lett 1986;196:96-102.
8.
Recht B, Frangione E, van Loghem E: Structural studies of a human gamma 3 myeloma protein (Goe) that binds staph protein A. J Immunol 1981;127:917-923.
9.
Takahashi N, Ishii I: Comparative structural study of N-linked oligosaccharides of human normal and pathological immunoglobulin G. Biochemistry 1987;26:1137-1144.
10.
Robert F, Mignucci M, McCurdy SA, Maldonado N, Lee JY: Hemostatic abnormalities associated with monoclonal gammopathies. Am J Med Sci 1993;306:359-366.
11.
Khamlichi AA, Aucoutrier P, Preudhomme JL, Cogne M: Structure of abnormal heavy chains in human heavy-chain-deposition disease. Eur J Biochem 1995;229:54-60.
12.
Liebman AH: Hemostatic defects associated with dysproteinemias; in Hoffman R et al: Hematology, Basic Principles and Practice, ed 4. New York, Churchill Livingstone, 2005, pp 2183-2187.
13.
Shinagawa A, Kojima H, Berndt MC, Kaneko S, Suzukawa K, Hasegawa Y, Shigeta O, Nagasawa T: Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor. Thromb Haemost 2005;93:889-896.
14.
Czestochowska E, Tyminski W, Gorski J, Umiastowski J: Disturbance of platelet function in patients with multiple myeloma. Folia Haematol Int Mag Klin Morphol Blutforsch 1987;114:845-851.
15.
Dmoszynska-Giannopoulou A, Kowalewski J, Sokolowska B: Disorders of blood platelet homeostasis in patients with multiple myeloma before the treatment and during remission. Pol Arch Med Wewn 1990;84:378-382.
16.
Salzman EW: Measurment of platelet adhesiveness: a simple in vitro technique demonstrating an abnormality in von Willebrand's disease. J Lab Lin Med 1963;62:724.
17.
Born GVR, Gross MJ: The aggregation of blood platelets. J Physiol 1963;168:178-195.
18.
Johansen BG: Agarose gel electrophoresis. Scand J Clin Lab Invest 1972;29:7-19.
19.
Radl J, Hoogeveen CM: Immunoblotting with (sub)class specific antibodies reveales a high frequency of monoclonal gammapathies in persons thought to be immunodeficent. Clin Chem 1988;34:1839-1842.
20.
Sagan Z: The application of Rivanol for serum transferin and immunoglobulin G determination. Clin Chim Acta 1968;21:225-230.
21.
Mejbaum-Katzenellenbogen W: Turbidimetricna micrometoda oznaczania bialek tanina. Acta Biochem Pol 1995;2:279-294.
22.
McDonagh PF, Hokama JY, Gale SC, Logan JJ, Davis-Gorman G, Goldman S, Copeland JG: Chronic expression of platelet adhesion proteins is associated with severe ischemic heart disease in type 2 diabetic patients: chronic platelet activation in diabetic heart patients. J Diabetes Complications 2003;17:269-278.
23.
Parquet-Gernez A, Kacem M: Platelet abnormalities in dysproteinemias. Nouv Rev Fr Hematol 1976;16:437-442.
24.
Wallace MR, Simon SR, Ershler WB, Burns SL: Haemorrhagic diathesis in multiple myeloma. Acta Haematol 1984;72:340-342.
25.
Spicka I, Cieslar P, Dyr JE, Matousova O: Hemostasis disorders in monoclonal gammopathies. Sb Lek 1991;93:277-286.
26.
Kasturi J, Saraya AK: Platelet functions in dysproteinaemia. Acta Haematol 1997;59:104-113.
27.
Freedman M, Merret R, Pruzanski W: Human monoclonal immunoglobulins with antibody-like activity. Immunochemistry 1976;13:193-202.
28.
Dighiero G: Autoimunity and B-cell malignancies. Hematol Cell Ther 1998;40:1-9.
29.
Di Minno G, Corragio F, Cerbone AM, Capitanio AM, Manzo C, Spina M, Scarpato P, Dattoli GM, Mattioli PL, Mancini M: A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest 1986;77:157-164.
30.
Perkins HA, MacKenzie MR, Fudenberg HH: Hemostatic defects in dysproteinemias. Blood 1970;35:695-707.
31.
Coleman M, Vigliano EM, Weksler ME, Nachman RL: Inhibition of fibrin monomer polymerization by lambda myeloma globulins. Blood 1972;39:210-223.
32.
Eby C: Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol 2009;145:151-163.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.